



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

28 June 2018
EMA/CHMP/BMWP/94528/2005 Rev. 1
Committee for Medicinal Products for Human Use (CHMP)

Annex to Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues

Guideline on similar medicinal products containing somatropin

Draft agreed by BMWP	March 2005
Adopted by CHMP for release for consultation	May 2005
Start of public consultation	May 2005
End of consultation (deadline for comments)	31 October 2005
Agreed by BMWP Working Party	January 2006
Adopted by CHMP	22 February 2006
Date of coming into effect	01 June 2006
3Rs technical update	27 March 2018
Agreed by the BMWP	27 March 2018
Adopted by the CHMP	28 June 2018
Date coming into effect	01 January 2019



This is a technical update to reflect current best practise with regard to implementation of 3Rs approaches and it is not intended as a full revision of this guideline (only section 4 is affected). These changes are considered to be minor and uncontroversial and consequently a consultation phase was considered unnecessary.

Keywords	<i>somatropin, recombinant, similar biological medicinal products, comparability, non-clinical studies, clinical studies, indication, extrapolation</i>
-----------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------

Annex to Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues

Guideline on similar medicinal products containing somatropin

Table of contents

Executive summary	4
1. Introduction (background).....	4
2. Scope.....	4
3. Legal basis and relevant guidelines	5
4. Non-clinical Studies.....	5
4.1. In vitro studies.....	5
4.2. In vivo studies	5
5. Clinical Studies	5
5.1. Pharmacokinetic (PK) studies.....	5
5.2. Pharmacodynamic (PD) studies	6
5.3. Clinical efficacy studies	6
5.4. Clinical Safety	7
6. Pharmacovigilance Plan.....	7
7. Extrapolation of indication	7
8. References	7

Executive summary

The main aim of the guideline is to address the non-clinical and clinical requirements for somatropin-containing medicinal products claiming to be similar to another one already marketed. The non-clinical section addresses the pharmaco-toxicological assessment. The clinical section addresses the requirements for pharmacokinetic, pharmacodynamic, efficacy and safety studies as well as the risk management plan. Criteria for extrapolation of clinical data to other indications approved for the reference medicinal product are discussed.

1. Introduction (background)

The Marketing Authorisation (MA) application dossier of a new recombinant human growth hormone (rhGH, somatropin) claimed to be similar to a reference medicinal product already authorised shall provide the demonstration of comparability of the product applied for to a reference medicinal product authorised in the EU.

The principal bioactive human growth hormone (hGH) is a single chain non-glycosylated 191 amino acid, 22 kD polypeptide produced in the anterior pituitary gland. Growth hormone for clinical use has an identical amino acid sequence and is produced by recombinant technology using *E. coli*, mammalian cells or yeast cells as expression system. The structure and biological activity of somatropin can be characterised by appropriate physico-chemical and biological methods. Several techniques and bioassays are available to characterise both the active substance and product-related substances/impurities such as deamidated and oxidized forms and aggregates.

Growth hormone has potent anabolic, lipolytic and anti-insulin effects (acute insulin-like effect). The effects of GH are mediated both directly (e.g. on adipocytes and hepatocytes) and indirectly via stimulation of insulin-like growth factors (principally IGF-1). Somatropin-containing medicinal products are currently licensed for normalising or improving linear growth and/or body composition in GH-deficient and certain non GH-deficient states. The same receptors are thought to be involved in all currently approved therapeutic indications of rhGHs.

Somatropin has a wide therapeutic window in children during the growth phase whereas adults may be more sensitive for certain adverse effects. Antibodies to somatropin have been described, including, very rarely, neutralising antibodies. Problems have been associated with the purity and stability of the formulations. Somatropin is administered subcutaneously; possible patient-related risk factors of immune response are unknown.

In accordance with the provisions of the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes and Directive 2010/63/EU on protection of animals used for scientific purposes, the 3R principles (replacement, reduction and refinement) should be applied to development of medicinal products.

2. Scope

The guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMA/CPMP/42832/05/) lays down the general requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy.

This product specific guidance is an Annex to the above guideline and presents the current view of the CHMP on the application of the guideline for demonstration of comparability of two recombinant human somatropin-containing medicinal products.

This Guideline should be read in conjunction with the requirements laid down in the EU Pharmaceutical legislation and with relevant CHMP guidelines (see section 7).

3. Legal basis and relevant guidelines

This Guideline should be read in conjunction with the introduction and general principles of Annex I to Directive 2001/83/EC, as amended, and all other relevant EU and ICH guidelines. These include, but are not limited to:

Directive 2001/83/EC, as amended and Part II of the Annex I of Directive 2001/83/EC, as amended.

4. Non-clinical studies

As regards non-clinical development, a stepwise approach should be applied to evaluate the similarity of the biosimilar and reference medicinal product.

Non-clinical studies should be performed before initiating clinical trials. In vitro studies should be conducted first and a decision then made as to the extent of what, if any, in vivo work will be required. General guidance on the stepwise approach is provided in the "Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues". The approach taken will need to be fully justified in the non-clinical overview.

4.1. In vitro studies

In order to compare differences in biological activity between the similar and the reference medicinal product, data from comparative bioassays should be provided, including receptor-binding studies and functional assays (e.g. cell proliferation assays in human cell lines). Wherever possible, analytical methods should be standardised and validated according to relevant guidelines.

4.2. In vivo studies

Generally, in vivo studies in animals are not recommended.

Measurement of pharmacokinetic and pharmacodynamic parameters is expected to be included in clinical studies and similar studies in animals are usually not expected to contribute additional relevant information to the biosimilarity exercise. Such studies as well as toxicological studies should only be considered in specific cases, as explained in the "Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues".

5. Clinical studies

5.1. Pharmacokinetic (PK) studies

The relative pharmacokinetic properties of the similar biological medicinal product and the reference medicinal product should be determined in a single dose crossover study using subcutaneous administration. Healthy volunteers are considered appropriate but suppression of endogenous GH production e.g. with a somatostatin analogue should be considered. The primary pharmacokinetic

parameter is AUC and the secondary parameters are C_{max} and $T_{1/2}$. Comparability margins have to be defined a priori and appropriately justified.

5.2. Pharmacodynamic (PD) studies

Pharmacodynamics should preferably be evaluated as part of the comparative pharmacokinetic study. The selected dose should be in the linear ascending part of the dose-response curve. IGF-1 is the preferred pharmacodynamic marker for the activity of somatropin and is recommended to be used in comparative pharmacodynamic studies. In addition, other markers such as IGFBP-3 may be used. On the other hand, due to the lack of a clear relationship between serum IGF-1 levels and growth response, IGF-1 is not a suitable surrogate marker for the efficacy of a somatropin in clinical trials.

5.3. Clinical efficacy studies

Clinical comparability efficacy between the similar biological medicinal product and the reference medicinal product should be demonstrated in at least one adequately powered, randomised, parallel group clinical trial. Clinical studies should be double-blind to avoid bias. If this is not possible, at minimum the person performing height measurements should be effectively masked to treatment allocation.

Sensitivity to the effects of somatropin is higher in GH-deficient than non-GH-deficient conditions. Treatment-naïve children with GH deficiency are recommended as the target study population as this provides a sensitive and well-known model. Study subjects should be pre-pubertal before and during the comparative phase of the trial to avoid interference of the pubertal growth spurt with the treatment effect. This may be achieved e.g. by limiting the age/bone age at study entry. It is important that the study groups are thoroughly balanced for baseline characteristics, as this will affect the sensitivity of the trial and the accuracy of the endpoints.

(Change in) height velocity or (change in) height velocity standard deviation score from baseline to the pre-specified end of the comparative phase of the trial is the recommended primary efficacy endpoint. Height standard deviation score is a recommended secondary endpoint. Adjustment for factors known to affect the growth response to somatropin should be considered.

During the comparative phase of the study, standing height should be measured at least 3 times per subject at each time point and the results averaged for analyses. The use of a validated measuring device is mandatory. Consecutive height measurements should be standardised and performed approximately at the same time of the day, by the same measuring device and preferably by the same trained observer. These recommendations aim to reduce measurement errors and variability.

For the determination of reliable baseline growth rates, it is important that also height measurements during the pre-treatment phase are obtained in a standardised manner using a validated measuring device.

Due to significant variability in short-term growth, seasonal variability in growth and measurement errors inherent in short-term growth measurements, the recommended duration of the comparative phase is at least 6 months and may have to be up to 12 months.

Calculation of pre-treatment growth rates should be based on observation periods of no less than 6 and no more than 18 months.

Comparability margins have to be pre-specified and appropriately justified, primarily on clinical grounds, and serve as the basis for powering the study.

5.4. Clinical Safety

Data from patients in the efficacy trial(s) are usually sufficient to provide an adequate pre-marketing safety database.

The applicant should provide comparative 12-month immunogenicity data of patients who participated in the efficacy trial(s) with sampling at 3-month intervals and testing using validated assays of adequate specificity and sensitivity.

In addition, adequate blood tests including IGF-1, IGFBP-3, fasting insulin and blood glucose should be performed.

6. Pharmacovigilance Plan

Within the authorisation procedure the applicant should present a risk management programme / pharmacovigilance plan in accordance with current EU legislation and pharmacovigilance guidelines. This should take into account risks identified during product development and potential risks, especially as regards immunogenicity, and should detail how these issues will be addressed in post-marketing follow-up.

7. Extrapolation of indication

Demonstration of efficacy and safety in GH-deficient children may allow extrapolation to other indications of the reference medicinal product if appropriately justified by the applicant.

8. References

- Directive 2001/83/EC, as amended.
- Part II of the Annex I of Directive 2001/83/EC, as amended.
- Guideline on similar biological medicinal products (CHMP/437/04/draft).
- Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMA/CPMP/42832/05/draft).
- Note for guidance on repeated dose toxicity (CPMP/SWP/1042/99).
- Note for guidance on toxicokinetics: A Guidance for assessing systemic exposure in toxicological studies (CPMP/ICH/384/95).
- Note for guidance on non-clinical local tolerance testing of medicinal products (CPMP/SWP/2145/00).
- Guideline on risk management systems for medicinal products for human use (EMA/CHMP 96286/2005)
- Note for Guidance on Good Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (CPMP/ICH/377/95)
- ICH Note for Guidance on Planning Pharmacovigilance Activities (CPMP/ICH/5716/03 - Final approval by CHMP on PHV)